Trinity Biotech Unveils Plans for Innovative CGM+ Biosensor Platform

Trinity Biotech, a clinical diagnostic developer, has announced its intentions to enter the personal diabetes management market with a groundbreaking wearable continuous glucose monitor (CGM) set to become the company's flagship product. The new CGM+ platform aims to revolutionize chronic disease management by combining glucose monitoring with additional health tracking features.

Advanced Biosensor Technology

The core of Trinity Biotech's CGM+ platform is a subdermal, electrochemical glucose reader. This innovative device goes beyond traditional glucose monitoring by incorporating sensors to track multiple health metrics, including:

• Heart rate
• Body temperature
• Sleep patterns
• Physical activity

This comprehensive approach to health monitoring positions the CGM+ as more than just a diabetes management tool, but as a holistic health tracking system.

AI-Driven Health Ecosystem

CEO John Gillard emphasized the transformative potential of the CGM+ platform, stating, "CGM+ is not just a device—it's a proprietary data engine we are building for the AI health ecosystem." The company envisions the technology powering the next wave of personalized, predictive, and preventative care.

By leveraging artificial intelligence and the extensive data collected by the CGM+ sensors, Trinity Biotech aims to open new commercial pathways, ranging from device sales to AI-driven data services. This strategic move is expected to position the company at the intersection of chronic disease management, digital health, and consumer wellness.

Development Timeline and Market Potential

Trinity Biotech has outlined an ambitious development and commercialization plan for the CGM+ platform:

• A pre-pivotal trial of the glucose sensor technology has recently been completed
• Results from this trial are expected to be announced in the near future
• The company is targeting a commercial launch for mid-2026

This timeline suggests a rigorous development process to ensure the platform's effectiveness and reliability before entering the market. The extended development period also allows Trinity Biotech to refine its AI capabilities and data analysis tools, potentially giving it a competitive edge in the rapidly evolving digital health landscape.

As the company prepares for this significant product launch, it has also taken steps to strengthen its financial position. Trinity Biotech recently announced expectations to become cash-flow-positive by the end of September, following a strategic consolidation and offshoring of its manufacturing and corporate services.

With its diverse portfolio of diagnostic products and its ambitious plans for the CGM+ platform, Trinity Biotech is positioning itself as a significant player in the future of personalized healthcare and chronic disease management.